The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase AlfaDavid Kronn, Anaïs Brassier, François Labarthe et al.|The Journal of Pediatrics|2025Cited by 3
Using a novel measuring device to objectively evaluate the clinical benefit on ptosis in infantile-onset Pompe disease (IOPD): Results from 145 weeks' avalglucosidase alfa dosing in Mini-COMET participants previously treated with alglucosidase alfaPriya S. Kishnani, S. Grace Prakalapakorn, Marguerite C. Weinert et al.|Molecular Genetics and Metabolism|2024Cited by 0